Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

In This Article:

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

●RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.●HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pioneering telehealth and direct-to-consumer healthcare solutions.
●RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.●HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pioneering telehealth and direct-to-consumer healthcare solutions.

MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and Hims & Hers Health Inc. (NYSE: HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.

  • RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.

  • HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pioneering telehealth and direct-to-consumer healthcare solutions.

“RKLX and HIMZ offer compelling opportunities for investors seeking amplified exposure to Rocket Lab and Hims & Hers, two companies driving innovation in their respective industries,” said Sylvia Jablonski, CEO of Defiance ETFs. “With increasing demand for satellite technology and digital healthcare solutions, Rocket Lab and Hims & Hers continue to play key roles in shaping the future of space exploration and telehealth.”

For more information, visit DefianceETFs.com

These Funds are not intended to be used by, and are not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Funds pursue a daily leveraged investment objective, making them riskier than alternatives that do not use leverage, as they magnify the performance of their respective underlying securities. These Funds are not suitable for all investors. They are designed for knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, recognize the risks associated with the use of leverage, and are willing to frequently monitor their portfolios. Over periods longer than a single day, the Funds may lose value even if their underlying securities increase in performance, and they will lose value if the underlying securities remain flat. An investor could lose the full principal value of their investment within a single day.

An investment in RKLX is not an investment in Rocket Lab USA, Inc. An investment in HIMZ is not an investment in Hims & Hers Health Inc.

About Defiance ETFs

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs.